Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

Open Access 01-01-2016 | Review

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer

Authors: Lingling Guo, Yongsheng Zhang, Lifeng Zhang, Fengbo Huang, Jinfan Li, Shouli Wang

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Inflammatory cells and mediators form a major part of the tumor microenvironment and play important roles in the regulation of cancer initiation, tumor cell proliferation, and metastasis. MicroRNAs (miRNAs) play important roles in several physiological and pathological processes, including the regulation of the inflammatory microenvironment in cancer. Transforming growth factor-β (TGF-β) is an inflammation-related cytokine that functions in both tumor suppression and promotion; however, its underlying molecular mechanisms remain unclear. Recent evidence indicates an association between miRNAs and TGF-β signaling, providing new insight into the nature of the inflammatory microenvironment in cancer. The present review is an overview of the interaction between miRNAs and inflammatory cytokines, with emphasis on the cross talk between TGF-β signaling and miRNAs and their influence on cancer cell behavior. The emerging roles of miRNAs in cancer-related inflammation and the potential to target miRNA signaling pathways for cancer therapy are also discussed.
Literature
1.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.PubMed
2.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMed
3.
Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2010;585:2087–99.PubMed
4.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.PubMedPubMedCentral
5.
6.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMed
7.
Kloosterman WP, Plasterk RHA. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–50.PubMed
8.
Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martinez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J Off Publ Fed Am Soc Exp Biol. 2015;29:3595–611.
9.
O'Connell RM, Rao DS, Baltimore D. MicroRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295–312.PubMed
10.
11.
Tili E, Michaille JJ, Calin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci. 2008;5:73–9.PubMedPubMedCentral
12.
Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol. 2008;33:312–5.PubMed
13.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMed
14.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMed
15.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMed
16.
Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–71.PubMedPubMedCentral
17.
Zhou X, Tang J, Cao H, Fan H, Li B: Tissue resident regulatory t cells: novel therapeutic targets for human disease. Cell Mol Immunol 2015
18.
19.
Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33 Suppl 1:S79–84.PubMed
20.
21.
22.
O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of toll-like receptor signalling. Nat Rev Immunol. 2011;11:163–75.PubMed
23.
Butz H, Rácz K, Hunyady L, Patócs A. Crosstalk between tgf-β signaling and the microRNA machinery. Trends Pharmacol Sci. 2012;33:382–93.PubMed
24.
Sivadas VP, Kannan S. The microRNA networks of tgfbeta signaling in cancer. Tumour Biol. 2014;35:2857–69.PubMed
25.
Tili E, Croce CM, Michaille JJ. Mir-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 2009;28:264–84.PubMed
26.
Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, et al. Mir-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma. 2014;61:241–51.PubMed
27.
Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of mir-155 and mir-125b levels following lipopolysaccharide/tnf-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179:5082–9.PubMed
28.
Xue H, Hua LM, Guo M, Luo JM. Ship1 is targeted by mir-155 in acute myeloid leukemia. Oncol Rep. 2014;32:2253–9.PubMed
29.
Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, et al. Mir-155 regulates ifn-gamma production in natural killer cells. Blood. 2012;119:3478–85.PubMedPubMedCentral
30.
Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, et al. Serum mir-21, mir-29a and mir-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21:4234–42.
31.
Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao YC, et al. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival. Tumour Biol. 2015;36:8159–66.PubMed
32.
Luo S, Wang J, Ma Y, Yao Z, Pan H. Ppargamma inhibits ovarian cancer cells proliferation through upregulation of mir-125b. Biochem Biophys Res Commun. 2015;462:85–90.PubMed
33.
Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, et al. Selective targeting of irf4 by synthetic microrna-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015. doi:10.​1038/​leu.​2015.​124.PubMedCentral
34.
Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, et al. Negative regulation of tlr4 via targeting of the proinflammatory tumor suppressor pdcd4 by the microRNA mir-21. Nat Immunol. 2010;11:141–7.PubMed
35.
Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving nf-kappab, lin28, let-7 microRNA, and il6 links inflammation to cell transformation. Cell. 2009;139:693–706.PubMedPubMedCentral
36.
Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21. Chinese J Cancer. 2011;30:371–80.
37.
38.
Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–22.PubMedPubMedCentral
39.
Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med. 2011;15:14–23.PubMedPubMedCentral
40.
Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, et al. A synonymous variant in irgm alters a binding site for mir-196 and causes deregulation of irgm-dependent xenophagy in crohn's disease. Nat Genet. 2011;43:242–5.PubMed
41.
Yang G, Han D, Chen X, Zhang D, Wang L, Shi C, et al. Mir-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of ikappabalpha both in vitro and in vivo. Neuro-Oncology. 2014;16:652–61.PubMedPubMedCentral
42.
Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C. MicroRNA-210 negatively regulates lps-induced production of proinflammatory cytokines by targeting nf-kappab1 in murine macrophages. FEBS Lett. 2012;586:1201–7.PubMed
43.
44.
Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, et al. Elevated expression of mir-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9:e89223.PubMedPubMedCentral
45.
Chen WX, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J Gastrointest Pathophysiol. 2014;5:63–70.PubMedPubMedCentral
46.
Ebrahimi F, Gopalan V, Smith RA, Lam AK. Mir-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2014;96:98–107.PubMed
47.
Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, et al. Reduced mir-126 expression facilitates angiogenesis of gastric cancer through its regulation on vegf-a. Oncotarget. 2014;5:11873–85.PubMedPubMedCentral
48.
Li D, Wang A, Liu X, Meisgen F, Grunler J, Botusan IR, et al. MicroRNA-132 enhances transition from inflammation to proliferation during wound healing. J Clin Invest. 2015;125:3008–26.PubMedPubMedCentral
49.
Wang ZH, Zhang QS, Duan YL, Zhang JL, Li GF, Zheng DL. Tgf-beta induced mir-132 enhances the activation of tgf-beta signaling through inhibiting smad7 expression in glioma cells. Biochem Biophys Res Commun. 2015;463:187–92.PubMed
50.
Labbaye C, Testa U. The emerging role of mir-146a in the control of hematopoiesis, immune function and cancer. J Hematol Oncol. 2012;5:13.PubMedPubMedCentral
51.
Li J, Yang H, Li Y, Liu Y, Chen S, Qi C, et al. MicroRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. Exp Mol Pathol. 2014;96:195–9.PubMed
52.
53.
Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in e(mu)-mir155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103:7024–9.PubMedPubMedCentral
54.
Cremer TJ, Ravneberg DH, Clay CD, Piper-Hunter MG, Marsh CB, Elton TS, et al. Mir-155 induction by f. Novicida but not the virulent f. Tularensis results in ship down-regulation and enhanced pro-inflammatory cytokine response. PLoS One. 2009;4:e8508.PubMedPubMedCentral
55.
Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (tnf{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. 2011;286:1436–44.PubMed
56.
Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100:8621–3.PubMedPubMedCentral
57.
Akhurst RJ, Derynck R. Tgf-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001;11:S44–51.PubMed
58.
59.
Hata A, Davis BN. Control of microRNA biogenesis by tgfbeta signaling pathway-a novel role of smads in the nucleus. Cytokine Growth Factor Rev. 2009;20:517–21.PubMedPubMedCentral
60.
Davis BN, Hata A. Regulation of microRNA biogenesis: a miriad of mechanisms: cell communication and signaling. CCS. 2009;7:18.PubMedPubMedCentral
61.
62.
Davis BN, Hilyard AC, Lagna G, Hata A. Smad proteins control drosha-mediated microRNA maturation. Nature. 2008;454:56–61.PubMedPubMedCentral
63.
Heldin CH, Moustakas A. Role of smads in tgfbeta signaling. Cell Tissue Res. 2011;347:21–36.PubMed
64.
Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by drosha. Mol Cell. 2010;39:373–84.PubMedPubMedCentral
65.
Wang W, Li J, Zhu W, Gao C, Jiang R, Li W, et al. MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer. 2014;14:819.PubMedPubMedCentral
66.
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, et al. Context-dependent bidirectional regulation of the muts homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol Cancer Res. 2010;8:1633–42.PubMedPubMedCentral
67.
Monfared H, Ziaee SA, Hashemitabar M, Khayatzadeh H, Kheyrollahi V, Tavallaei M, et al. Co-regulated expression of tgf-beta variants and mir-21 in bladder cancer. Urol J. 2013;10:981–7.PubMed
68.
Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets. 2013;17:1073–80.PubMed
69.
Wang J, Li Y, Wang X, Jiang C. Ursolic acid inhibits proliferation and induces apoptosis in human glioblastoma cell lines u251 by suppressing tgf-beta1/mir-21/pdcd4 pathway. Basic Clin Pharmacol Toxicol. 2012;111:106–12.PubMed
70.
Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, et al. Tgfbeta-mediated upregulation of hepatic mir-181b promotes hepatocarcinogenesis by targeting timp3. Oncogene. 2010;29:1787–97.PubMed
71.
Brockhausen J, Tay SS, Grzelak CA, Bertolino P, Bowen DG, d'Avigdor WM, et al. Mir-181a mediates tgf-beta-induced hepatocyte emt and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int. 2014;35:240–53.PubMed
72.
Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and atm. Oncogene. 2011;30:1470–80.PubMed
73.
Neel JC, Lebrun JJ. Activin and tgfbeta regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cell Signal. 2013;25:1556–66.PubMed
74.
Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of pten. J Immunol. 2012;188:5500–10.PubMed
75.
Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, et al. Down-regulation of microRNA-494 via loss of smad4 increases foxm1 and beta-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology. 2014;147:485–97. e418.PubMed
76.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.PubMed
77.
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of mir-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28:341–7.PubMedPubMedCentral
78.
79.
Han X, Yan S, Weijie Z, Feng W, Liuxing W, Mengquan L, et al. Critical role of mir-10b in transforming growth factor-beta1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther. 2014;21:60–7.PubMed
80.
Ouyang H, Gore J, Deitz S, Korc M. MicroRNA-10b enhances pancreatic cancer cell invasion by suppressing tip30 expression and promoting egf and tgf-beta actions. Oncogene. 2014;33:4664–74.PubMed
81.
Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, et al. Tgf-beta-associated mir-27a inhibits dendritic cell-mediated differentiation of th1 and th17 cells by tab3, p38 mapk, map2k4 and map2k7. Genes Immun. 2012;13:621–31.PubMed
82.
Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, et al. Tgf-beta-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014;111:4203–8.PubMedPubMedCentral
83.
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, et al. Tgf-beta induces mir-182 to sustain nf-kappab activation in glioma subsets. J Clin Invest. 2012;122:3563–78.PubMedPubMedCentral
84.
Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/smad pathway and contributes to epithelial cell plasticity by targeting rhoa. Mol Cell Biol. 2008;28:6773–84.PubMedPubMedCentral
85.
Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, et al. Mir-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun. 2008;376:86–90.PubMed
86.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.PubMed
87.
Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012;2:414–33.PubMedPubMedCentral
88.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting zeb1 and sip1. Nat Cell Biol. 2008;10:593–601.PubMed
89.
Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Devedec SE, et al. Beta1 integrin inhibition elicits a prometastatic switch through the tgfbeta-mir-200-zeb network in e-cadherin-positive triple-negative breast cancer. Sci Signal. 2014;7:ra15.PubMed
90.
Izumchenko EG, Chang X, Michailidi C, Kagohara LT, Ravi R, Paz K, et al. The tgfbeta-mir200-mig6 pathway orchestrates the emt-associated kinase switch that induces resistance to egfr inhibitors. Cancer Res. 2014;74:3995–4005.PubMedPubMedCentral
91.
Maroof H, Salajegheh A, Smith RA, Lam AK. MicroRNA-34 family, mechanisms of action in cancer: a review. Curr Cancer Drug Targets. 2014;14:737–51.PubMed
92.
Dimopoulos K, Gimsing P, Gronbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol. 2013;91:95–105.PubMed
93.
Yang P, Li Q-J, Feng Y, Zhang Y, Markowitz G, Ning S, et al. Tgf-β-mir-34a-ccl22 signaling-induced treg cell recruitment promotes venous metastases of hbv-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.PubMedPubMedCentral
94.
Sonkoly E, Wei T, Pavez Lorie E, Suzuki H, Kato M, Torma H, et al. Protein kinase c-dependent upregulation of mir-203 induces the differentiation of human keratinocytes. J Invest Dermatol. 2010;130:124–34.PubMed
95.
Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M, et al. Mir-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 2014;35:5953–63.PubMed
96.
Xu M, Gu M, Zhang K, Zhou J, Wang Z, Da J. Mir-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of fgf2. Diagn Pathol. 2015;10:24.PubMedPubMedCentral
97.
Ding X, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor beta (tgf-beta) and transcription factor snai2 represses expression of microRNA mir-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem. 2013;288:10241–53.PubMedPubMedCentral
98.
Ueno K, Hirata H, Shahryari V, Chen Y, Zaman MS, Singh K, et al. Tumour suppressor microRNA-584 directly targets oncogene rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer. 2011;104:308–15.PubMed
99.
Fils-Aime N, Dai M, Guo J, El-Mousawi M, Kahramangil B, Neel JC, et al. MicroRNA-584 and the protein phosphatase and actin regulator 1 (phactr1), a new signaling route through which transforming growth factor-beta mediates the migration and actin dynamics of breast cancer cells. J Biol Chem. 2013;288:11807–23.PubMedPubMedCentral
100.
Sun MM, Li JF, Guo LL, Xiao HT, Dong L, Wang F, et al. Tgf-[beta]1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014;33:2075–86.PubMed
101.
Martin J, Jenkins RH, Bennagi R, Krupa A, Phillips AO, Bowen T, et al. Post-transcriptional regulation of transforming growth factor beta-1 by microRNA-744. PLoS One. 2011;6:e25044.PubMedPubMedCentral
102.
Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (tgf)-beta1 restores growth inhibitory tgf-beta signaling through microRNAs. J Biol Chem. 2011;286:16447–58.PubMedPubMedCentral
103.
Dogar AM, Semplicio G, Guennewig B, Hall J. Multiple microRNAs derived from chemically synthesized precursors regulate thrombospondin 1 expression. Nucleic Acid Ther. 2014;24:149–59.PubMedPubMedCentral
104.
Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the emt and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29:4237–44.PubMed
105.
Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S. The role of microRNA-128a in regulating tgfbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 2010;124:89–99.PubMedPubMedCentral
106.
Jiang X, Xiang G, Wang Y, Zhang L, Yang X, Cao L, et al. MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting tgf-beta rii. Mol Cells. 2012;33:545–51.PubMedPubMedCentral
107.
Feng B, Dong TT, Wang LL, Zhou HM, Zhao HC, Dong F, et al. Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One. 2012;7:e43452.PubMedPubMedCentral
108.
Lo SS, Hung PS, Chen JH, Tu HF, Fang WL, Chen CY, et al. Overexpression of mir-370 and downregulation of its novel target tgfbeta-rii contribute to the progression of gastric carcinoma. Oncogene. 2011;31:226–37.PubMed
109.
Chu TH, Yang CC, Liu CJ, Lui MT, Lin SC, Chang KW. Mir-211 promotes the progression of head and neck carcinomas by targeting tgfbetarii. Cancer Lett. 2013;337:115–24.PubMed
110.
Yu Y, Kanwar SS, Patel BB, Oh P-S, Nautiyal J, Sarkar FH, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (ttgf-β r2) in colon cancer cells. Carcinogenesis. 2012;33:68–76.PubMed
111.
Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor ii (tgfbr2) expression in prostate cancer. Oncogene. 2014;33:4097–106.PubMed
112.
Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting nf-kappab and tgf-beta signaling pathways. Oncogene. 2011;31:4150–63.PubMed
113.
Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, et al. Mir-655 is an emt-suppressive microRNA targeting zeb1 and tgfbr2. PLoS One. 2013;8:e62757.PubMedPubMedCentral
114.
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, et al. MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting tgfbetar2 in nsclc. PLoS One. 2014;9:e94639.PubMedPubMedCentral
115.
Jiang F, Mu J, Wang X, Ye X, Si L, Ning S, et al. The repressive effect of mir-148a on tgf beta-smads signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. PLoS One. 2014;9:e96698.PubMedPubMedCentral
116.
Turcatel G, Rubin N, El-Hashash A, Warburton D. Mir-99a and mir-99b modulate tgf-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS One. 2012;7:e31032.PubMedPubMedCentral
117.
Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y, Zhou LF. The mir-92b functions as a potential oncogene by targeting on smad3 in glioblastomas. Brain Res. 2013;1529:16–25.PubMed
118.
Geraldo MV, Yamashita AS, Kimura ET. MicroRNA mir-146b-5p regulates signal transduction of tgf-beta by repressing smad4 in thyroid cancer. Oncogene. 2012;31:1910–22.PubMed
119.
Zhang Y, Fan K-J, Sun Q, Chen A-Z, Shen W-L, Zhao Z-H, et al. Functional screening for miRNAs targeting smad4 identified mir-199a as a negative regulator of tgf-β signalling pathway. Nucleic Acids Res. 2012;40:9286–97.PubMedPubMedCentral
120.
Hager M, Pedersen CC, Larsen MT, Andersen MK, Hother C, Gronbaek K, et al. MicroRNA-130a-mediated down-regulation of smad4 contributes to reduced sensitivity to tgf-beta1 stimulation in granulocytic precursors. Blood. 2011;118:6649–59.PubMed
121.
Liu L, Nie J, Chen L, Dong G, Du X, Wu X, et al. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting smad4 expression. PLoS One. 2013;8:e55532.PubMedPubMedCentral
122.
Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, et al. MicroRNA regulatory network inference identifies mir-34a as a novel regulator of tgf-β signaling in glioblastoma. Cancer Disc. 2012;2:736–49.
123.
Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C, et al. Targeting smad4 links microRNA-146a to the tgf-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol. 2010;92:129–35.PubMed
124.
Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of smad5 links microRNA-155 to the tgf-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A. 2010;107:3111–6.PubMedPubMedCentral
125.
Jiang D, Aguiar RC. MicroRNA-155 controls rb phosphorylation in normal and malignant b lymphocytes via the noncanonical tgf-beta1/smad5 signaling module. Blood. 2014;123:86–93.PubMedPubMedCentral
126.
Liu Y, Sun R, Lin X, Liang D, Deng Q, Lan K. Kaposi's sarcoma-associated herpesvirus-encoded microRNA mir-k12-11 attenuates transforming growth factor beta signaling through suppression of smad5. J Virol. 2012;86:1372–81.PubMedPubMedCentral
127.
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, et al. The mir-106b-25 cluster targets smad7, activates tgf-beta signaling, and induces emt and tumor initiating cell characteristics downstream of six1 in human breast cancer. Oncogene. 2012;31:5162–71.PubMedPubMedCentral
128.
Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets pten and smad7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58:629–41.PubMed
129.
Petrocca F, Vecchione A, Croce CM. Emerging role of mir-106b-25/mir-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68:8191–4.PubMed
130.
Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2f1-regulated microRNAs impair tgfbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–86.PubMed
131.
Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The mir-17-92 microRNA cluster regulates multiple components of the tgf-beta pathway in neuroblastoma. Mol Cell. 2010;40:762–73.PubMedPubMedCentral
132.
Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, et al. Mir-183 inhibits tgf-beta1-induced apoptosis by downregulation of pdcd4 expression in human hepatocellular carcinoma cells. BMC Cancer. 2010;10:354.PubMedPubMedCentral
133.
Pollari S, Leivonen SK, Perala M, Fey V, Kakonen SM, Kallioniemi O. Identification of microRNAs inhibiting tgf-beta-induced il-11 production in bone metastatic breast cancer cells. PLoS One. 2012;7:e37361.PubMedPubMedCentral
134.
Jiang H, Jin C, Liu J, Hua D, Zhou F, Lou X, et al. Next generation sequencing analysis of miRNAs: miR-127-3p inhibits glioblastoma proliferation and activates tgf-beta signaling by targeting ski. OMICS. 2014;18:196–206.PubMedPubMedCentral
135.
136.
Mu Y, Gudey SK, Landstrom M. Non-smad signaling pathways. Cell Tissue Res. 2012;347:11–20.PubMed
137.
Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles—diagnostic and therapeutic implications (review). Int J Oncol. 2015;46:17–27.PubMed
138.
139.
Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13.PubMedPubMedCentral
140.
Squadrito ML, Baer C, Burdet F, Maderna C, Gilfillan GD, Lyle R, et al. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell Rep. 2014;8:1432–46.PubMed
141.
Le MT, Hamar P, Guo C, Basar E, Perdigao-Henriques R, Balaj L, et al. Mir-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014;124:5109–28.PubMedPubMedCentral
142.
Neviani P, Fabbri M. Exosomic microRNAs in the tumor microenvironment. Frontiers Med. 2015;2:47.
143.
Eugenia CY: Interaction of salicylates and the other nonsteroidal anti-inflammatory agents with breast cancer endocrine treatment: Systematic review. Am J Clin Oncol 2014:in press.
144.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.PubMed
145.
Shi L, Wang L, Hou J, Zhu B, Min Z, Zhang M, et al. Targeting roles of inflammatory microenvironment in lung cancer and metastasis. Cancer Metastasis Rev. 2015;34:319–31.PubMed
146.
Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22:33–40.PubMed
Metadata
Title
MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer
Authors
Lingling Guo
Yongsheng Zhang
Lifeng Zhang
Fengbo Huang
Jinfan Li
Shouli Wang
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4374-2

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Research Article

Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma

Original Article

CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p

Research Article

The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma

Original Article

H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation

Original Article

Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy

Review

Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits